“For the six months ended June 28, 2025, net cash used in financing activities was primarily driven by distribution to partners of $303 million, repayment for long-term borrowings of $19 million, and Class B Unit repurchases of $15 million.”10-Q · Aug 5, 2026 ↗
Medline Inc.
MDLN
Market read
Medline Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 2 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 8 directly disclosed connections are confirming.
- Tariff refunds and sales growth lifted Medline Brand Segment Adjusted EBITDA, while tariffs raised import costs and headcount investments raised compensation expense.
Invalidation: The isolated read changes if MDLN's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 2 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 8 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- Tariff refunds and sales growth lifted Medline Brand Segment Adjusted EBITDA, while tariffs raised import costs and headcount investments raised compensation expense.
Company research
Understand the business, not just the ticker
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
- Latest annual revenue changed +11.5% year over year.
- Operating cash flow covered net income at 1.50x in the latest annual period.
No qualifying adverse evidence was identified; that is not proof there is no downside.
- P/E is 55% below the available filing-peer median; determine whether growth and quality justify the difference.
- EV/sales is 45% below the available filing-peer median; determine whether growth and quality justify the difference.
Price as of Sep 10, 2026
32.39Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
Persistent and emerging business drivers
“Selling, General, and Administrative Expenses SG&A expenses for the six months ended June 27, 2026 increased $380 million, or 17.7%, to $2,523 million, compared to $2,143 million for the respective period in 2025, primarily due to $248 million of higher compe…”10-Q · Aug 5, 2026 ↗
“Changes in working capital resulted in net cash used of $324 million, which is primarily driven by an increase in other assets of $279 million related to the IEEPA tariff refund receivable, and an increase in trade accounts receivable of $148 million due to s…”10-Q · Aug 5, 2026 ↗
“For the six months ended June 28, 2025, net cash used in investing activities was primarily driven by net capital expenditures of $208 million and payments for asset acquisitions of $33 million.”10-Q · Aug 5, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 0.9× · EV/sales 1.3×. Comparisons use only industry-matched filing peers.
Fewer than 4 annual revenue periods; too little history to scaffold scenarios.
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 10:35 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for MDLN. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for MDLN. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind MDLN
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ECLEcolab Inc.supplierFeb 25, 2026 ▾
“During 2024, we acquired the global surgical solutions business of Ecolab, Inc., including industry-leading Microtek product lines (“Microtek”), and Sinclair Dental Co.”
CAHCardinal Health, Inc.distributorFeb 25, 2026 ▾
“Additionally, other distributors of med-surg products similarly connect the fragmented supplier and provider bases and aggregate inventory from suppliers to deliver products to customers, such as McKesson, Cardinal Health, Owens & Minor, and Henry Schein.”
Depended on by
AVNS15.0% of AVNScustomerFeb 24, 2026 ▾
“In the year ended December 31, 2025, sales to Medline Industries accounted for approximately 12% of consolidated net sales.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 9 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
MDLN is currently a Early Follower in the organic co-movement group Medical Devices. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.